Understanding how certain cells affect the immune response to brain tumors after radiation therapy
Role of FAP-positive cells in immune response to irradiated glioblastoma
This study is looking at how certain cells in the body, called FAP+ cells, affect the immune system's response to glioblastoma, a tough brain tumor, to find better ways to make cancer treatments work after radiation therapy, and patients may be involved to help discover new treatment options.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10825590 on NIH RePORTER |
What this research studies
This research investigates the role of fibroblast activating protein-positive (FAP+) cells in the immune response to glioblastoma, a type of aggressive brain tumor. The study aims to understand how these cells contribute to the tumor's ability to resist treatment, particularly after radiation therapy. By examining the immune suppression caused by FAP+ cells, the researchers hope to identify new strategies to enhance the effectiveness of existing cancer therapies. Patients may be involved in this research to help uncover mechanisms that could lead to improved treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are undergoing or have undergone radiation therapy.
Not a fit: Patients with other types of brain tumors or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While the role of FAP+ cells in other cancers has been studied, this specific investigation in glioblastoma is relatively novel and untested.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Vanpouille-Box, Claire Isabelle — Weill Medical Coll of Cornell Univ
- Study coordinator: Vanpouille-Box, Claire Isabelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.